Related Experiment Video
Updated: Jun 13, 2025

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
SMS2 siRNA inhibits pancreatic tumor growth by tumor microenvironment modulation
Xin Jiang1, Ziqing Yuan2, Tingbo Ding2
1Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, China.
Abstract:
The massive infiltration of suppressor immune cells within the tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is a major cause of treatment resistance. Reducing this infiltration may represent a potentially effective therapeutic strategy. Sphingomyelin synthase 2 (SMS2) is a crucial enzyme for sphingomyelin synthesis, contributing significantly to the integrity and function of the plasma membrane. In this study, we developed a self-assembling SMS2 siRNA gene expression plasmid for in vivo delivery. The SMS2 siRNA specifically inhibits SMS2 expression while preserving the expression and activity of SMS1. Administration of the self-assembling SMS2 siRNA suppresses tumor growth in a murine model of Panc02 pancreatic carcinoma, modulates the polarization of tumor-associated macrophages (TAMs), and reduces the infiltration of tumor-associated neutrophils (TANs) by regulating the NF-κB/CXCL5 pathway. Consequently, utilizing SMS2 siRNA to improve the local immunosuppressive microenvironment holds promise for pancreatic cancer therapy.
Insights
Targeting sphingomyelin synthase 2 (SMS2) with siRNA gene therapy can reduce immune cell infiltration in pancreatic cancer. This approach suppresses tumor growth and improves the tumor microenvironment for potential pancreatic cancer treatment.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) exhibits significant treatment resistance due to suppressor immune cell infiltration in the tumor microenvironment (TME).
- Sphingomyelin synthase 2 (SMS2) plays a key role in sphingolipid metabolism and plasma membrane integrity.
Purpose of the Study:
- To develop and evaluate a self-assembling SMS2 siRNA gene expression plasmid for in vivo delivery.
- To investigate the therapeutic potential of SMS2 inhibition in a pancreatic cancer model.
Main Methods:
- Development of a self-assembling plasmid encoding SMS2 siRNA for targeted gene silencing.
- In vivo administration of SMS2 siRNA in a murine Panc02 pancreatic carcinoma model.
- Analysis of tumor growth, immune cell polarization (TAMs), immune cell infiltration (TANs), and associated signaling pathways (NF-κB/CXCL5).
Main Results:
- SMS2 siRNA specifically inhibited SMS2 expression while sparing SMS1.
- Administration of SMS2 siRNA suppressed tumor growth in the murine model.
- SMS2 siRNA modulated tumor-associated macrophage polarization and reduced tumor-associated neutrophil infiltration.
- The NF-κB/CXCL5 pathway was implicated in the observed immunomodulatory effects.
Conclusions:
- Targeting SMS2 with siRNA represents a viable strategy to overcome treatment resistance in pancreatic cancer.
- Modulating the immunosuppressive TME via SMS2 inhibition holds promise for pancreatic cancer therapy.
Related Concept Videos
MicroRNAs
The Tumor Microenvironment
Abnormal Proliferation

